|
Escalating conflict in West Asia is prompting Indian hospitals to rapidly rethink their international care models, accelerating the rollout of AI-enabled remote monitoring, expanded teleconsultation services, and contingency evacuation protocols to support overseas cancer patients requiring complex treatment.
Jojis Mathew, centre head, Cyteacare Hospitals, said the protracted Middle East conflicts are reshaping oncology medical tourism to India, profoundly affecting patients from Saudi Arabia, Kuwait, and Oman seeking our world-class care for cancers like breast, colorectal, and lung. These individuals rely on India for rapid diagnostics like NGS-based tumour profiling, minimally invasive surgeries: HIPEC for peritoneal cancers, and tailored post-operative regimens including targeted therapies, delivered with cultural affinity and English proficiency.
War-induced disruptions, airport closures, Red Sea shipping halts, and regional instability, have caused a 50% drop in Middle East oncology patients. Patients endure prolonged waits for clearances, escalating flight costs up 200%, and drug shortages from disrupted imports. Post-operative travel for surveillance scans or adjuvant chemo is now perilous, forcing many into suboptimal home treatments or costly diversions to Turkey and Singapore, he added.
To counter this, Indian hospitals are rolling out AI-driven remote monitoring, cross-border clinical trials, and dedicated oncology evacuation protocols. Government incentives like the Ayushman Bharat Digital Mission enable secure data sharing with Gulf providers, while bilateral MoUs could fast-track visas, Mathew told Pharmabiz in an email.
This downturn, while painful, accelerates India's oncology self-sufficiency: boosting proton therapy centres and biosimilar production. We have treated many international patients annually pre-war; post-recovery strategies could double that. Ultimately, India's compassionate, cost-effective ecosystem, coupled with geopolitical healing, will restore trust, ensuring Middle East patients continue choosing us for hope and healing amid global turmoil, he noted.
According to Dr Mounika Reddy, consultant medical oncology and Dr. Santhosh Kumar B, consultant surgical oncology, Prakriya Hospitals, the ongoing wars in the Middle East, particularly in regions like Gaza and Lebanon, have severely disrupted medical tourism for oncology care in India, hitting patients from Gulf countries hardest. Traditionally, patients from the UAE, Saudi Arabia, and Qatar flock to India for advanced diagnostics like PET-CT scans, precision surgeries such as robotic prostatectomies, and comprehensive post-operative care including immunotherapy and rehabilitation, often at 30-50% lower costs than in their home countries.
However, escalating conflicts have grounded flights, imposed travel bans, and heightened insurance restrictions, slashing inbound patient volumes by an estimated 40-60% in the past year. Families face visa delays, supply chain issues for newer drugs and immunotherapy like serplulimab and toripalimab, psychological barriers amid safety fears. This has led to treatment deferrals, with some patients opting for harmful local options or overburdened European hubs, pointed out Mathew and Dr Reddy.
India's response must prioritize telemedicine bridges, expedited medical visas via e-Medical Visa 2.0, and partnerships with Gulf insurers for seamless continuity. Hospitals are adapting with virtual tumour boards and hybrid care models, ensuring follow-ups without physical travel. Long-term, this crisis underscores India's need for self-reliant oncology infrastructure, like expanding LINAC availability and indigenous CAR-T therapies, said Dr Reddy.
Despite challenges, India's 1.4 million annual cancer cases position us as a resilient hub. By fostering peace diplomacy ties and digital health corridors, we can reclaim our edge, save lives and boost a $10 billion medical tourism sector. The war tests us, but innovation will prevail, said Dr Kumar.
|